Recent publications by Researchers affiliated with the Centre for Tropical Medicine and Global Health
Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV).
Jittamala P. et al, (2025), EClinicalMedicine, 80
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
Schilling WHK. et al, (2024), PLoS medicine, 21
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)
Wongnak P. et al, (2024), The Lancet Infectious Diseases, 24, 953 - 963
Adverse events associated with benznidazole treatment for Chagas disease in children and adults.
Cruz CV. et al, (2024), British journal of clinical pharmacology
Phase 2 pilot trial to optimise pharmacometric evaluations in Chagas disease (CHARM: CHAgas disease PharMacometrics)
Cruz CV. et al, (2024), Wellcome Open Research, 9, 342 - 342
Comparison of WHO versus national COVID-19 therapeutic guidelines across the world: not exactly a perfect match
Cokljat M. et al, (2024), BMJ Global Health, 9, e014188 - e014188
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial
Luvira V. et al, (2024), BMC Infectious Diseases, 24
An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi-infected children. A retrospective cohort study.
Abal M. et al, (2024), PLoS neglected tropical diseases, 18
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
Schilling WHK. et al, (2024), The Lancet Infectious Diseases, 24, 36 - 45
Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)
Jittamala P. et al, (2023), The Journal of Infectious Diseases, 228, 1318 - 1325
Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)
Schilling WHK. et al, (2023), eLife, 12
Assessment of the nlmixr R package for population pharmacokinetic modeling: A metformin case study
Mak WY. et al, (2023), British Journal of Clinical Pharmacology, 89, 330 - 339
Systematic Review of Early Phase Pediatric Clinical Pharmacology Trials
Subramanian D. et al, (2022), The Journal of Pediatric Pharmacology and Therapeutics, 27, 609 - 617
Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19
Schilling WHK. et al, (2022)
An Ultrafast Ultrahigh-Performance Liquid Chromatography Coupled With Tandem Mass Spectrometry Method for Cannabidiol Monitoring in Pediatric Refractory Epilepsy
Pérez Montilla CA. et al, (2021), Therapeutic Drug Monitoring, 43, 712 - 717
COVID-19 chemoprevention
Cruz C. and White NJ., (2021), International Journal of Infectious Diseases, 107, 31 - 33